Takeda signs antibody therapy deal with HiFiBiO

According to the agreement, scientists from both companies will work together to discover antibodies against Takeda’s targets using HiFiBiO Therapeutics’ single-cell screening capabilities. Takeda will be responsible for the preclinical and clinical development of the discovered antibodies.

HiFiBiO Therapeutics will receive upfront, R&D, milestone, and royalty payments based on antibodies delivered to Takeda for development and commercialisation. Specific financial terms of the transaction were not disclosed.

"Takeda is a world leader in oncology, gastroenterology and neuroscience therapeutics," said Liang Schweizer, president and CEO of HiFiBiO. "This multi-target partnership further validates our ongoing commitment to these types of open-innovation collaborations to better address unmet medical needs around the world."

-----------------------------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.